Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models

Medical Decision Making

Volumn 37, Issue 7, 2017, Pages 790-801

  Olchanski, Natalia ^a   Cohen, Joshua T ^a   Neumann, Peter J ^a   Wong, John B ^a   Kent, David M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

group decision making; outcomes research; quality of care; translating research into practice

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; HEART INFARCTION; HUMAN; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 85028631838     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17704855     Document Type: Article

References (44)

1. Rothwell PM,. Can overall results of clinical trials be applied to all patients? Lancet. 1995; 345: 1616-9.
2. Kent DM, Hayward RA,. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007; 298: 1209-12.
3. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA,. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010; 11: 85.
4. Kravitz RL, Duan N, Braslow J,. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004; 82: 661-87.
5. Espinoza MA, Manca A, Claxton K, Sculpher MJ,. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making. 2014; 34: 951-64.
6. Basu A, Meltzer D,. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007; 27: 112-27.
7. van Gestel A, Grutters J, Schouten J, et al. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. Value Health. 2012; 15: 13-21.
8. Claxton K,. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999; 18: 341-64.
9. Van Calster B, Vickers AJ,. Calibration of risk prediction models: impact on decision-analytic performance. Med Decis Making. 2015; 35: 162-9.
10. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329: 673-82.
11. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995; 332: 1418-24.
12. Kent DM, Hayward RA, Griffith JL, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002; 113: 104-11.
13. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP,. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol. 2004; 57: 843-52.
14. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA,. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol. 2016 3, DOI: 10.1093/ije/dyw118.
15. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
16. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-33.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-97.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288: 2998-3007.
19. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980; 243: 661-9.
20. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996; 335: 217-25.
21. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001; 344: 1659-67.
22. National Heart, Lung, and Blood Institute. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982; 247: 1707-14.
23. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324: 781-8.
24. Lipid Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251: 351-64.
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
26. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-33.
27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
28. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003; 289: 3106-16.
29. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation. 2011; 123: 1763-70.
30. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359: 2429-41.
31. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979; 242: 2562-71.
32. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-9.
33. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982; 248: 1465-77.
34. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387-98.
35. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006; 355: 2395-407.
36. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351: 2058-68.
37. Bulger EM, May S, Brasel KJ, et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA. 2010; 304: 1455-64.
38. Bulger EM, May S, Kerby JD, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011; 253: 431-41.
39. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991; 265: 3255-64.
40. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685-91.
41. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302.
42. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989; 320: 618-27.
43. Ioannidis JP, Garber AM,. Individualized cost-effectiveness analysis. PLoS Med. 2011; 8: e1001058.
44. Meltzer D,. Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ. 2001; 20: 109-29.